Research paperDiscovery of 6′-chloro-N-methyl-5’-(phenylsulfonamido)-[3,3′-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium
Graphical abstract
Introduction
Drug resistant malaria infections are still a severe threat to the public health [1]. In clinic, there is yet a great demand to seek novel chemotypes with new mechanisms of antimalaria in order to overcome the drug resistance. In recent years, new chemical entities with activity across different life cycle stages of the malaria parasite and new mechanisms of action have been identified [[2], [3], [4], [5], [6]]. Plasmodium phosphatidylinositol-4-kinase [3,6] is one of the attractive drug discovery targets due to its important roles in all stages of the Plasmodium lifecycle. In addition, it has been expected that the Plasmodium PI4K inhibitors would overcome the resistance of artemisinin and artemisinin-based combination therapies for P. falciparum malaria since they bear different inhibition mechanism [[7], [8], [9], [10]]. Plasmodium PI4K catalyzes the phosphorylation of phosphatidylinositol (PI) to produce the cellular secondary messenger phosphatidylinositol-4-phosphate (PI4P), subsequently initiating a cascade of downstream events to modulate a variety of biological processes including secondary messenger signaling, cellular membrane remodeling, and vesicular trafficking [11]. A number of Plasmodium PI4K kinase inhibitors with different chemotypes such as MMV390048 (1) [6], which is now under Phase II clinical trial [12], KAI407 (2) [13], KAI715 (3) [14], KDU731 (4) [15], KDU691 (5) [3], UCT943 (6) [16], BRD73842 (7) [17], BQR695 (8) [3], and 9 [18] have been disclosed in patents and research articles over the past several years (Fig. 1). In this study, we report the discovery of a novel bipyridine-sulfonamide chemotype PfPI4K inhibitor compound 15g (CHMFL-PI4K-127), which is obtained from optimizing a chloro-bipyridine chemotype based hit compound 15a (Fig. 2).
Section snippets
Chemistry
The synthesis of compounds 15a-g was depicted in Scheme 1. The intermediate 12a was obtained from 10a via N-Boc group protection (11a) and Miyaura borylation reaction. The pyrrolopyridine 10b was protected with acetyl chloride to give 11b, and then Miyaura borylation reaction afforded the intermediate 12b. 13 reacted with benzenesulfonyl chloride to provide sulfonamide 14, which was then converted to compounds 15a-g through Suzuki-Miyaura cross coupling reaction. As shown in Scheme 2, compounds
Conclusions
In summary, we have discovered a novel chemotype based PfPI4K kinase inhibitor compound 15g, which exhibited potent enzyme and parasite inhibitory activities. In addition, it displayed high selectivity over human lipid and protein kinases which indicated better therapeutic safety window. 15g also showed activity across a panel of clinical drug-resistant isolates and therefore might have a low risk for pre-existing cross-resistance. In the blood-stage malaria model, 15g resulted in 100%
Chemistry
All reagents and solvents were purchased from commercial sources and were used as received unless specified otherwise, or prepared as described in the literature. All moisture sensitive reactions were carried out using dry solvents under ultrapure argon protection. Glassware was dried in an oven at 140 °C for at least 12 h prior to use and then assembled quickly while hot, sealed with rubber septa, and allowed to cool under a stream of argon. Reactions were stirred magnetically using
Author contributions
The manuscript was written through contributions of all the authors. All the authors have given approval to the final version of the manuscript. X.L., Z.J., Z.H., and F.L. contributed equally to this work.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (Grant Nos, 81872745, 81773777, 81872748, 31771455, 81271863), the National Key Research and Development Program of China (Grant No. 2016YFA0400900), the Natural Science Foundation of Anhui Province (Grant No. 1908085QH348), the China Postdoctoral Science Foundation (Grant No. 2019M652057), the Frontier Science Key Research Program of CAS (Grant No. QYZDB-SSW-SLH037), the Innovative Program of Development Foundation of
References (28)
- et al.
Homology modeling and virtual screening for inhibitors of lipid kinase PI(4)K from Plasmodium
Biomed. Pharmacother.
(2016) - et al.
Pam 1392 [2,4-diamino-6-(3,4-dichlorobenzylamino) quinazoline] as a chemotherapeutic agent -Plasmodium berghei, P cynomolgi, P Knowlesi, and Trypanosoma Cruzi
Exp. Parasitol.
(1969) Word Malaria Report
(2017)Priming the antimalarial pipeline
Nature
(2010)- et al.
Targeting Plasmodium PI(4)K to eliminate malaria
Nature
(2013) - et al.
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Nature
(2015) - et al.
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Sci. Transl. Med.
(2015) - et al.
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase
Sci. Transl. Med.
(2017) - et al.
Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination
Parasite
(2018) - et al.
Plasmodium falciparum resistance to Artemisinin derivatives and Piperaquine: a major challenge for malaria elimination in Cambodia
Am. J. Trop. Med. Hyg.
(2016)
A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria
Nature
Artemisinin resistance in Plasmodium falciparum malaria
N. Engl. J. Med.
Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery
BMC Evol. Biol.
MMV390048 POC in patients with P. vivax and P. falciparum malaria
Cited by (12)
Specific sub fractions from Terminalia mantaly (H. Perrier) extracts potently inhibit Plasmodium falciparum rings, merozoite egress and invasion
2022, Journal of EthnopharmacologyCitation Excerpt :Unfortunately, most of the approved antimalarial drugs do not fulfil all these requirements of which the ability for multiple life cycle-stage inhibitory potential has been the toughest to achieve. Moreover, while several advances in research on small molecules may achieve these important objectives (Baragaña et al., 2015; Kato et al., 2016; Pino et al., 2017; Liang et al., 2020), a single drug targeting all the life cycle stages of malaria parasites is unavailable for clinical use (Tse et al., 2019) due to the inherent complexity of the life cycle of malaria parasites. Furthermore, the recent shift in focus from malaria control to total eradication highlights the necessity for alternative antimalarials with specific activity profiles (Ellis et al., 2021).
Trends of antimalarial marine natural products: progresses, challenges and opportunities
2022, Natural Product ReportsAn insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins
2021, European Journal of Medicinal ChemistryCitation Excerpt :Further optimization of the best compound to improve pharmacokinetics and parasite clearance may lead to the study in a clinical trial. Towards the contribution of PfPI4K inhibitors, Liang, et al. [246] diversified and reported the bipyridine-sulfonamide scaffold to develop potent anti-plasmodial agents with subnanomolar potency. The study dealt with the synthesis of more than thirty new compounds as inhibitors of PfPI4K in which compound 35 was reported with the best potency as IC50 = 0.9 nM and EC50 = 25.1 nM against Pf3D7 strain while EC50 = 23–47 nM against different drug-resistant strains.
Design and synthesis of fosmidomycin analogs containing aza-linkers and their biological activity evaluation
2024, Pest Management ScienceAntimalarial drug discovery: progress and approaches
2023, Nature Reviews Drug DiscoveryAdvances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38
2023, British Journal of Pharmacology
- 1
These authors contribute equally.